Your science is ready.
Your timelines aren't.

A 50-person biotech burns $2–5M per month. Operational inefficiencies that extend regulatory timelines, slow clinical site activation, or miss grant windows don't just waste time — they consume runway that could fund the next data readout.

Phase 2 readouts, NDA filings, first approvals — these are the moments that multiply your company's value and unlock better financing terms. Six months of operational drag is six months before that inflection point arrives. The science isn't causing the delay. The operations are.

Regulatory drafting. Clinical site communications. Contract routing. Grant research. The same functions bleed time at every biotech. The companies that move fastest aren't smarter — they've eliminated the operational tax on their scientific talent.

Where do you need to be?

We map your 12, 24, and 36-month milestones — the readouts, filings, and financing events that define success for your board and investors. This is the fixed point everything else is measured against.

Where is time being lost?

We identify exactly where your team is spending hours on work that doesn't advance those goals. Usually it's regulatory, clinical ops, and G&A — and it's almost always measurable in days and dollars once you know where to look.

AI where it earns its place

Sometimes the fix is process redesign. Sometimes it's purpose-built AI agents. Usually both. We build what actually moves your timeline, not what's easiest to demo. Then we train your team to run it without us.